RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Trial details
- Registry ID
- NCT05733611
- Phase
- Phase 2
The FDA approved atezolizumab on 18 May 2016.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCNCT05733611 | Replimune, Inc. | Phase 2 | Terminated | 2025-08-18Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2016-05-18Day | atezolizumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761034", "applicant_as_listed_by_fda": "GENENTECH INC", "brand_names": ["TECENTRIQ"], "active_ingredients": ["ATEZOLIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20160518", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |